vs

Side-by-side financial comparison of Cheniere Energy Partners, L.P. (CQP) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.2B vs $2.9B, roughly 1.1× Cheniere Energy Partners, L.P.). Cheniere Energy Partners, L.P. runs the higher net margin — 44.2% vs 37.3%, a 6.9% gap on every dollar of revenue. On growth, Cheniere Energy Partners, L.P. posted the faster year-over-year revenue change (18.3% vs 9.5%). Cheniere Energy Partners, L.P. produced more free cash flow last quarter ($864.0M vs $348.6M). Over the past eight quarters, Cheniere Energy Partners, L.P.'s revenue compounded faster (12.6% CAGR vs 8.9%).

Total revenue of oil and gas companies is listed in billions of U.S. dollars. Total revenue is usually self-reported by companies, and often reported by neutral, unbiased, reliable publications. Reported data may be subsequently revised or restated due to a wide range of issues such as exchange rates, contract settlements, or mid-year discontinuation of products or services. Fiscal years are for January 1 to December 31, except where noted. Empty cells indicate that no data for that year has ...

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

CQP vs VRTX — Head-to-Head

Bigger by revenue
VRTX
VRTX
1.1× larger
VRTX
$3.2B
$2.9B
CQP
Growing faster (revenue YoY)
CQP
CQP
+8.7% gap
CQP
18.3%
9.5%
VRTX
Higher net margin
CQP
CQP
6.9% more per $
CQP
44.2%
37.3%
VRTX
More free cash flow
CQP
CQP
$515.4M more FCF
CQP
$864.0M
$348.6M
VRTX
Faster 2-yr revenue CAGR
CQP
CQP
Annualised
CQP
12.6%
8.9%
VRTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CQP
CQP
VRTX
VRTX
Revenue
$2.9B
$3.2B
Net Profit
$1.3B
$1.2B
Gross Margin
85.4%
Operating Margin
50.5%
37.8%
Net Margin
44.2%
37.3%
Revenue YoY
18.3%
9.5%
Net Profit YoY
106.6%
30.5%
EPS (diluted)
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CQP
CQP
VRTX
VRTX
Q4 25
$2.9B
$3.2B
Q3 25
$2.4B
$3.1B
Q2 25
$2.5B
$3.0B
Q1 25
$3.0B
$2.8B
Q4 24
$2.5B
$2.9B
Q3 24
$2.1B
$2.8B
Q2 24
$1.9B
$2.6B
Q1 24
$2.3B
$2.7B
Net Profit
CQP
CQP
VRTX
VRTX
Q4 25
$1.3B
$1.2B
Q3 25
$506.0M
$1.1B
Q2 25
$553.0M
$1.0B
Q1 25
$641.0M
$646.3M
Q4 24
$623.0M
$913.0M
Q3 24
$635.0M
$1.0B
Q2 24
$570.0M
$-3.6B
Q1 24
$682.0M
$1.1B
Gross Margin
CQP
CQP
VRTX
VRTX
Q4 25
85.4%
Q3 25
86.5%
Q2 25
86.3%
Q1 25
86.9%
Q4 24
85.5%
Q3 24
85.8%
Q2 24
85.9%
Q1 24
87.3%
Operating Margin
CQP
CQP
VRTX
VRTX
Q4 25
50.5%
37.8%
Q3 25
29.0%
38.6%
Q2 25
29.1%
38.8%
Q1 25
27.6%
22.7%
Q4 24
33.0%
35.2%
Q3 24
40.2%
40.3%
Q2 24
40.4%
-132.9%
Q1 24
38.1%
42.4%
Net Margin
CQP
CQP
VRTX
VRTX
Q4 25
44.2%
37.3%
Q3 25
21.0%
35.2%
Q2 25
22.5%
34.8%
Q1 25
21.4%
23.3%
Q4 24
25.3%
31.4%
Q3 24
30.9%
37.7%
Q2 24
30.1%
-135.8%
Q1 24
29.7%
40.9%
EPS (diluted)
CQP
CQP
VRTX
VRTX
Q4 25
$4.64
Q3 25
$4.20
Q2 25
$3.99
Q1 25
$2.49
Q4 24
$3.62
Q3 24
$4.01
Q2 24
$-13.92
Q1 24
$4.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CQP
CQP
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$182.0M
$6.6B
Total DebtLower is stronger
$14.2B
Stockholders' EquityBook value
$18.7B
Total Assets
$17.4B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CQP
CQP
VRTX
VRTX
Q4 25
$182.0M
$6.6B
Q3 25
$121.0M
$6.3B
Q2 25
$108.0M
$6.4B
Q1 25
$94.0M
$6.2B
Q4 24
$270.0M
$6.1B
Q3 24
$331.0M
$6.5B
Q2 24
$351.0M
$5.8B
Q1 24
$333.0M
$10.2B
Total Debt
CQP
CQP
VRTX
VRTX
Q4 25
$14.2B
Q3 25
$14.2B
Q2 25
$14.2B
Q1 25
$14.7B
Q4 24
$14.8B
Q3 24
$14.8B
Q2 24
$14.8B
Q1 24
$13.6B
Stockholders' Equity
CQP
CQP
VRTX
VRTX
Q4 25
$18.7B
Q3 25
$17.3B
Q2 25
$17.2B
Q1 25
$16.5B
Q4 24
$16.4B
Q3 24
$15.6B
Q2 24
$14.8B
Q1 24
$18.5B
Total Assets
CQP
CQP
VRTX
VRTX
Q4 25
$17.4B
$25.6B
Q3 25
$16.8B
$24.9B
Q2 25
$16.9B
$24.0B
Q1 25
$17.1B
$22.9B
Q4 24
$17.5B
$22.5B
Q3 24
$17.4B
$22.2B
Q2 24
$17.5B
$20.1B
Q1 24
$17.5B
$23.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CQP
CQP
VRTX
VRTX
Operating Cash FlowLast quarter
$887.0M
$498.0M
Free Cash FlowOCF − Capex
$864.0M
$348.6M
FCF MarginFCF / Revenue
29.7%
10.9%
Capex IntensityCapex / Revenue
0.8%
4.7%
Cash ConversionOCF / Net Profit
0.69×
0.42×
TTM Free Cash FlowTrailing 4 quarters
$2.6B
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CQP
CQP
VRTX
VRTX
Q4 25
$887.0M
$498.0M
Q3 25
$658.0M
$1.2B
Q2 25
$558.0M
$1.1B
Q1 25
$665.0M
$818.9M
Q4 24
$876.0M
$584.6M
Q3 24
$691.0M
$1.4B
Q2 24
$732.0M
$-3.8B
Q1 24
$669.0M
$1.3B
Free Cash Flow
CQP
CQP
VRTX
VRTX
Q4 25
$864.0M
$348.6M
Q3 25
$610.0M
$1.1B
Q2 25
$490.0M
$927.4M
Q1 25
$605.0M
$778.2M
Q4 24
$827.0M
$492.0M
Q3 24
$652.0M
$1.3B
Q2 24
$702.0M
$-3.8B
Q1 24
$633.0M
$1.2B
FCF Margin
CQP
CQP
VRTX
VRTX
Q4 25
29.7%
10.9%
Q3 25
25.4%
37.0%
Q2 25
20.0%
31.3%
Q1 25
20.2%
28.1%
Q4 24
33.6%
16.9%
Q3 24
31.7%
47.0%
Q2 24
37.1%
-144.5%
Q1 24
27.6%
46.0%
Capex Intensity
CQP
CQP
VRTX
VRTX
Q4 25
0.8%
4.7%
Q3 25
2.0%
3.3%
Q2 25
2.8%
4.9%
Q1 25
2.0%
1.5%
Q4 24
2.0%
3.2%
Q3 24
1.9%
2.4%
Q2 24
1.6%
2.6%
Q1 24
1.6%
2.5%
Cash Conversion
CQP
CQP
VRTX
VRTX
Q4 25
0.69×
0.42×
Q3 25
1.30×
1.15×
Q2 25
1.01×
1.04×
Q1 25
1.04×
1.27×
Q4 24
1.41×
0.64×
Q3 24
1.09×
1.31×
Q2 24
1.28×
Q1 24
0.98×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CQP
CQP

Liquefied Natural Gas$2.9B98%
Regasification Service$34.0M1%
Other$17.0M1%

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons